NEWS

CellPoint, L.L.C. announced today that it has entered into automated production agreement with KP Pharmaceutical Technologies for lead molecular imaging agent Oncardia®
CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with KP Pharmaceutical Technology, Inc. to produce 1mg vials of its lead agent Oncardia®(ethylenedicysteine-glucosamine).   CellPoint is currently completing Phase 2b and 3 nuclear imaging trials with 99mTc-Oncardia® in both cardiology and oncology imaging. The new formulation will […] ...
Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology
CENTENNIAL, Colo., August 24, 2016 – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic stress ...
Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia® for Cancer and Heart Disease Diagnostic Imaging
CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia® (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m […] ...
Cell>Point Announces Postive Results from 99mTc-Oncardia® (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cancer.
CENTENNIAL, Colo., January 15, 2015 - Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a  physician initiated IND study at the University of Chicago Medical Center. The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled ...
Cell>Point Announces Encouraging Results from 99mTc -EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease
CENTENNIAL, Colo., April 9, 2013 —Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled Ethylenedicysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of  schemia in patients with Coronary ...
Cell>Point and HYUN IMC Expand License in South Korea to Include Hanmi Pharmaceutical, Co., Ltd for Cancer and Heart Disease Imaging
Third License Completes the Company’s Initiative to Secure a Strong Pharmaceutical  Partner for the South Korean Market CENTENNIAL, Colo., March 11, 2013—Cell>Point announced today that it entered into a license agreement on December 17,2012 with Hanmi Pharmaceutical Co., Ltd (Hanmi) who is headquartered in Seoul, Korea. The license agreement also includes HYUN IMC as a party (who Cell>Point previously […] ...
Cardiology Imaging Technologies presents cardiology clinical trial data on EC-G at the American Society of Nuclear Cardiology 2012 Annual Conference
Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical trial abstract for its cardiology imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glocosamine), used to image ischemic patients during rest and exercise stress testing at the American Society of Nuclear Cardiology 2012 Meeting on September 6, 2012. ...
Cell>Point to Present at the 26th Indian Cooperative Oncology Network (ICON) Meeting in Bengaluru, India
CENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the 26th Indian Oncology Network (ICON) Meeting in Bengaluru, India, On Saturday, March 27, 2012, at 10:45 a.m. local time. The ICON meeting will be held at the Crowne Plaza in Bengaluru. https://www.cellpointweb.com/Press-Release-EC-G%20Cardio-1b-2-IND-Final.pdf ...
Cell>Point Announces Agreement with the FDA on a Special Protocol Assessment for the Phase 3 Technetium-99m-EC-G Lung Cancer Imaging Trial
CENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer. https://www.cellpointweb.com/spa-press-release-march-8-2012.pdf ...
Cell>Point Executes Asia License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent, Technetium-99m-EC-G
CENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for countries of the South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co.,Ltd., headquatered in Seoul, South Korea. https://www.cellpointweb.com/PR-Feb-28-2012.pdf ...
CENTENNIAL, Colo., January 24, 2012—Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”
Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.” The agreement leads with Cell>Point’s cancer and cardiology molecular imaging agent—EC-G or, specifically, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but covers the entire portfolio of products being developed by Cell>Point. EC-G has completed ...
CENTENNIAL, Colo., November 23, 2011
Cell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011 ...
CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G
https://www.cellpointweb.com/2011-SNM-Final.pdf ...
CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.
Embed Video ...
Cell>Point adds Dr. Wayne Yakes to Board of Advisors – 11/22/2010
CENTENNIAL, Colo., November 22, 2010 – Cell>Point is pleased to announce that Dr. Wayne Yakes has joined our Board of Advisors.  Dr. Yakes currently serves as the Director of the Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.  Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology […] ...
Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.
CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of […] ...
CENTENNIAL, Colo., March 18, 2010
Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan. ...
CENTENNIAL, Colo., June 21, 2010
Cell>Point announced today that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD). ...
CENTENNIAL, Colo., June 3, 2010
Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010. ...
CENTENNIAL, Colo., February 10, 2010
Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway. ...
Cell>Point receives approval for Beta Cell Technology patent – 6/23/2009
CENTENNIAL, Colo., June 23, 2009 – Cell>Point today announced that the U.S.P.T.O. approved its Beta Cell Technology U.S. patent application (App. No. 10/942,615). Cell>Point’s Beta Cell Technology is currently in preclinical testing at The University of Chicago Medical Center for imaging Type I Diabetes. ...
Cell>Point adds Steven Hanley to Board of Advisors – 6/18/2009
CENTENNIAL, Colo., June 18, 2009 – Cell>Point is pleased to announce that Steve Hanely has joined our Board of Advisors. Mr. Hanley is a former President of the Global Imaging Division of Covidien . Mr. Hanley earned his MBA and BS, Business Administration from Marquette University. ...
Cell>Point adds Dr. Eric Kurzweil to Board of Advisors – 9/11/2008
CENTENNIAL, Colo., September 11, 2008 – Cell>Point is pleased to announce that Eric Kurzweil, M.D., MBA has joined our Board of Advisors. Dr. Kurzweil is currently President of the Rocky Mountain Region of Pediatrix. Pediatrix, a $2.63 billion market cap company listed on the NYSE:PDX which includes more than 900 physicians nationwide. Dr. Kurzweil received […] ...
Cell>Point establishes European subsidiary — 7|1|08
Cell>Point announced today that it has established a subsidiary in the Netherlands, Cell>Point Netherlands BV. Cell>Point plans to expand its operation in Europe including financial partners and European clinical trial sites for its Phase III clinical trials in 99mTc-EC-G. ...
Cell>Point to present at Wachovia 2008 Healthcare Conference — 1|25|08
CENTENNIAL, Colo., January 25, 2008 – Cell>Point, L.L.C. today announced that it will present at the Wachovia 2008 Healthcare Conference, which will be held January 29-31, 2008, at The Langham Hotel in Boston, Mass. Cell>Point will present Thursday, January 31 at 1:00 pm (Eastern Time) in the Palmer Room. ...
Diagnostic Imaging April 2007 Article — 4|18|07
Cell>Point was featured in the Diagnostic Imaging April 2007 issue “Small biopharm company hatches plan to unseat FDG” according to Terry Colip, Managing Partner of Cell>Point. To view article go to www.diagnosticimaging.com April 2007 issue. ...
Dr. F. David Rollo joins Cell>Point as President — 9|12|06
CENTENNIAL, Colo., September 12, 2006 Cell>Point today announced F. David Rollo, M.D., Ph.D. has joined the company as President. Dr. Rollo was formerly Chief Medical Officer of Philips Medical Systems, a global leader in diagnostic imaging systems and healthcare information technology solutions. Cell>Point has licensed five radiopharmaceutical technology platforms from The University of Texas M.D […] ...
Cell>Point expands clinical trial for Imaging Myocardial Viability — 6|1|06
CENTENNIAL, Colo., June 1, 2006 -Cell>Point today announced it plans to start a Phase II clinical trial to evaluate the effectiveness of its 99mTc-EC-DG (Technetium-99m-Ethylenedicys-teine-Deoxyglucose) in diagnosing the presence of viable tissue in regions of the myocardium damaged by myocardial infarction or chronic coronary artery disease. The company has completed the Phase I safety trial ...
Cell>Point named Biotech Rising Star of the Year — 11|8|05
ENGLEWOOD, Colorado – November, 8, 2005 – Cell>Point was named Biotech “Rising Star of the Year” by the Colorado BioScience Association. ...
Cell>Point acquires Oligosaccharide Conjugate License — 6|3|05
HOUSTON, Texas – June 3, 2005 – Cell>Point obtained the worldwide patent and technology license to Oligosaccharide Conjugates for Dual Imaging and Radio/Chemotherapy developed at The University of Texas M. D. Anderson Cancer Center. This novel technology is facilitating the development of combination modality diagnostic imaging agents and new combination radio/chemotherapeutic agents for use in […] ...
Cell>Point featured in Aunt Minnie — 5|20|05
ENGLEWOOD,Colorado-May20,2005-Cell>Point was featured in the following Aunt Minnie article Biotech firm Cell>Point sees promise for oncology SPECT 1/20/2005 By: Kate Madden Yee Since PET imaging was introduced in the 1990s, its advocates have slowly but surely established a place for the technology, so much so that PET is now considered by many to be the […] ...
EC Technology featured in Basel, Switzerland — 4|21|05
HOUSTON, Texas – April 21, 2005 – Cell>Point announced today that David J. Yang, Ph.D. will present our EC Technology at the Joint Meeting of the Austrian, German, and Swiss Societies of Nuclear Medicine to be held in Basel, Switzerland (April 27-30, 2005). ...
Cell>Point to present at 30th Annual Deutsche Bank Health Care Conference — 4|20|05
Cell>Point to present at 30th Annual Deutsche Bank Health Care Conference -4|20|05 ENGLEWOOD, Colorado – April 20, 2005 -Cell>Point will be a presenting company at the 30th Annual Deutsche Bank Health Care Conference to be held in Baltimore, May 2-4, 2005. The webcast can be viewed at http://www.corporate-ir.net/ireye/confRegistration.zhtml?ticker=W189917&item_id=ew,1055963,1,189917,438136,524157,2&from ...
Cell>Point acquires N4 Technology License —3|1|05
HOUSTON, Texas – March 1, 2005 – Cell>Point obtained the worldwide patent and technology license on February 14, 2005 to tatraazacyclopentadecane (N4) technology developed at The University of Texas M.D. Anderson Cancer Center. N4 Technology will form the foundation for the development of Positron Emission Tomography imaging agents using generator based isotopes as well as […] ...
Cell>Point to Present at Rice Forum — 2|22|05
HOUSTON, Texas – February 22, 2005 – Cell>Point has been selected to be a presenting company at the 4th Annual Rice Alliance Life Science Technology Venture Forum on March 11, 2005 at Rice University. Greg R. Colip, President of the company, will present an overview of the company and its technology platforms. The Rice Alliance […] ...
Dr. Saad Zakko joins Scientific Advisory Board — 9|8|04
HOUSTON, Texas – September 1, 2004 ?Cell>Point is pleased to announce that Dr. Saad Zakko has joined our Scientific Advisory Board. Dr. Zakko has been Consultant to the Department of Nuclear Medicine at Dubai Hospital ...
Cell>Point completes clinical pilot study on 99mTc-EC-Annexin V — 4|1|04
Cell>Point L.L.C. completes clinical pilot study on 99mTc-EC-Annexin V at The University of Texas M.D. Anderson Cancer Center. The study evaluated the use of 99mTc-EC-Annexin V to assess tumor apoptosis (programmed cell death) in patients with primary breast cancer and to detect and image treatment related apoptosis in patients with primary breast cancer. ...
Royal Philips Electronics collaborates with Cell>Point — 9|29|03
HOUSTON, Texas – September 29, 2003 – Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced today that it will collaborate with Cell>Point, L.L.C, a biotechnology company based in Englewood, Colo., to optimize Cell>Point’s novel diagnostic imaging agent on Philips’ SKYLight & gantry-free gamma camera. The companies will share clinical trial costs to develop the best […] ...
Cell>Point L.L.C. Completes Exclusive License Negotiations for Second Technology Platform In Situ Hydrogel — 7|1|03
In July 2003, the company completed exclusive license negotiations with M.D. Anderson for a second technology platform, In Situ Hydrogel, which will be used for local regional chemotherapy and radiotherapy. In comparison with other hydrogel technologies, In Situ Hydrogel is the only hydrogel formulation capable of delivering a high yield load of a therapeutic radionuclide […] ...
Cell>Point L.L.C. Preparing to Conduct Studies — 10|1|02
HOUSTON, Texas - October 2002 - Cell>Point L.L.C. is preparing to commence clinical biokinetic and biodistribution studies at The University of Texas M.D. Anderson Cancer Center on 99mTc-EC-Metronidazole, 99mTc-EC-Annexin V and 99mTc-EC-Cox-2. If results from the studies are as expected, Cell>Point will prepare and submit IND applications with the FDA for the three "kit" compounds. ...
Cell>Point Receives Approval of its Investigations New Drug Application for 99mTc-EC-Deoxyglucose — 6|1|02
HOUSTON, Texas - June 2002 - Cell>Point L.L.C. (Englewood, CO) received approval of its Investigational New Drug Application for 99mTc-EC-Deoxyglucose (known in the clinical trial as "CP6262") from the FDA on June 26. The Phase I clinical trial will be conducted at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. CP6262 ...
Cell>Point, L.L.C. Executes Exclusive Worldwide Patent and Technology License Agreement for ethylenedicysteine — 7|1|01
HOUSTON, Texas – July 2001 – Cell>Point, L.L.C. executed an exclusive worldwide Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center for ethylenedicysteine (“EC”) drug conjugate technology which functions as a chemical bridge linking diagnostic radio-tracers or therapeutic radionuclides to ligand disease target seekers or novel FDA approved drugs. Technetium-99m-EC-deoxyglucose […] ...